Association of nicotinamide adenine dinucleotide phosphate oxidase p22phox gene 549C>T polymorphism with coronary artery disease

Chinese Medical Journal

Volumn 125, Issue 8, 2012, Pages 1416-1419

  Liu, Tong Tao ^a   Wang, Li Li ^b,c   Fang, Sheng Xia ^b   Jia, Chong Qi ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Dongying Center for Disease Control and Prevention   (China)

Author keywords

Coronary artery disease; Nicotinamide adenine dinucleotide phosphate oxidase; Oxidative stress; P22phox; Polymorphism

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTANT; P22PHOX GENE; POLYMERASE CHAIN REACTION; PYROSEQUENCING; RISK;

CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NADPH OXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84860467744     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.08.010     Document Type: Article

References (22)

1. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol 2005; 39: 667-679.
2. Mayer B, Erdmann J, Schunkert H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 2007; 96: 1-7.
3. Moreno MU, Zalba G. CYBA gene variants as biomarkers for coronary artery disease. Drug News Perspect 2010; 23: 316-324.
4. San Jose G, Fortuno A, Beloqui O, Diez J, Zalba G. NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci 2008; 114: 173-182.
5. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 2005; 25: 274-278.
6. Dworakowski R, Alom-Ruiz SP, Shah AM. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep 2008; 60: 21-28.
7. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci 2005; 109: 217-226.
8. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31 Suppl 2: s170-s180.
9. Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 1990; 86: 1729-1737.
10. Di Castelnuovo A, Soccio M, Iacoviello L, Evangelista V, Consoli A, Vanuzzo D, et al. The C242T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and a meta-analysis. Thromb Haemost 2008; 99: 594-601.
11. Fang S, Wang L, Jia C. Association of p22phox gene C242T polymorphism with coronary artery disease: a meta-analysis. Thromb Res 2010; 125: e197-e201.
12. Nikitin AG, Chistiakov DA, Minushkina LO, Zateyshchikov DA, Nosikov VV. Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. Heart Vessels 2010; 25: 229-236.
13. Nasti S, Spallarossa P, Altieri P, Garibaldi S, Fabbi P, Polito L, et al. C242T polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucasian Italians. Dis Markers 2006; 22: 167-173.
14. Fan M, Kähönen M, Rontu R, Lehtinen R, Viik J, Niemi M, et al. The p22phox C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study. Am Heart J 2006; 152: 538-542.
15. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744-1747.
16. Moreno MU, San Jose G, Fortuno A, Miguel-Carrasco JL, Beloqui O, Diez J, et al. The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. Front Biosci 2011; 3: 1467-1474.
17. Goliasch G, Wiesbauer F, Grafl A, Ponweiser E, Blessberger H, Tentzeris I, et al. The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease (≤40 years of age). Thromb Haemost 2011; 105: 529-534.
18. Bedard K, Attar H, Bonnefont J, Jaquet V, Borel C, Plastre O, et al. Three common polymorphisms in the CYBA gene form a haplotype associated with decreased ROS generation. Hum Mutat 2009; 30: 1123-1133.
19. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979; 59: 607-609.
20. Hathaway CA, Heistad DD, Piegors DJ, Miller FJ Jr. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 2002; 90: 277-283.
21. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998; 329: 653-657.
22. Fukui T, Yoshiyama M, Hanatani A, Omura T, Yoshikawa J, Abe Y. Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun 2001; 281: 1200-1206.